A new study has found that Wegovy, the weight-loss formulation of semaglutide, carries a significantly higher risk of a rare but serious eye condition compared to Ozempic, its lower-dose diabetes counterpart. The risk of non-arteritic anterior ischemic optic neuropathy—often called an "eye stroke"—is almost five times higher with Wegovy than with Ozempic.
The research, published in EurekAlert, analyzed adverse event reports to compare the safety profiles of different GLP-1 receptor agonist formulations. The findings reveal a stark difference: patients taking the higher dose of semaglutide for weight loss face substantially greater vision-related risks than those taking the same drug at lower doses for diabetes management.
The study also found gender differences in risk. Men taking these medications face a risk three times greater than women for developing this potentially blinding condition. Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when blood flow to the optic nerve is suddenly blocked, leading to permanent vision loss that typically cannot be reversed.
Understanding the dosage connection
The mechanism isn't entirely clear, but researchers suspect it may relate to the dosage—Wegovy is prescribed at 2.4 mg weekly for weight loss, while Ozempic maxes out at 2 mg weekly for diabetes, though many patients take lower doses. The higher the dose, the more pronounced the metabolic effects, which may influence blood flow to delicate ocular tissues.
What does this mean for the millions of people using GLP-1 drugs? First, it's important to keep the absolute risk in perspective. NAION is rare, affecting roughly 2-10 people per 100,000 annually in the general population. Even with a five-fold increase, the absolute risk remains relatively small. But for individuals already at risk—those with certain optic nerve anatomy, previous eye problems, or cardiovascular risk factors—this finding warrants serious consideration.
What patients should watch for
Patients taking Wegovy or Ozempic should watch for warning signs: sudden vision loss in one eye, often upon waking; decreased color vision; or visual field defects. These symptoms require immediate medical attention, as NAION can progress rapidly.
The findings don't necessarily mean people should stop taking these medications, which have proven extraordinarily effective for both diabetes control and weight loss, with significant cardiovascular benefits. But they do underscore the importance of informed consent and careful risk-benefit analysis, particularly for weight-loss use where the medical necessity may be less acute than for diabetes treatment.
